Metric Deep Dive: Understanding Replimune Group Inc (REPL) Through its Ratios

Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

After finishing at $11.69 in the prior trading day, Replimune Group Inc (NASDAQ: REPL) closed at $11.40, down -2.48%. In other words, the price has decreased by -$2.48 from its previous closing price. On the day, 0.72 million shares were traded. REPL stock price reached its highest trading level at $11.73 during the session, while it also had its lowest trading level at $11.25.

Ratios:

Our goal is to gain a better understanding of REPL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.11 and its Current Ratio is at 10.11. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.19.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, ROTH MKM on August 28, 2024, initiated with a Buy rating and assigned the stock a target price of $17.

On November 19, 2021, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $52.Piper Sandler initiated its Overweight rating on November 19, 2021, with a $52 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 16 ’24 when Hill Emily Luisa sold 8,938 shares for $10.18 per share. The transaction valued at 90,989 led to the insider holds 101,057 shares of the business.

Xynos Konstantinos sold 15,881 shares of REPL for $119,108 on Jun 07 ’24. The Chief Medical Officer now owns 117,131 shares after completing the transaction at $7.50 per share. On May 16 ’24, another insider, Sarchi Christopher, who serves as the Chief Commercial Officer of the company, sold 2,218 shares for $6.47 each. As a result, the insider received 14,350 and left with 92,252 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, REPL now has a Market Capitalization of 799800064 and an Enterprise Value of 424023872.

Stock Price History:

Over the past 52 weeks, REPL has reached a high of $12.97, while it has fallen to a 52-week low of $4.92. The 50-Day Moving Average of the stock is -0.49%, while the 200-Day Moving Average is calculated to be 26.34%.

Shares Statistics:

The stock has traded on average 629.26K shares per day over the past 3-months and 413990 shares per day over the last 10 days, according to various share statistics. A total of 61.42M shares are outstanding, with a floating share count of 52.46M. Insiders hold about 23.22% of the company’s shares, while institutions hold 90.84% stake in the company. Shares short for REPL as of 1730332800 were 7048962 with a Short Ratio of 11.20, compared to 1727654400 on 6067342. Therefore, it implies a Short% of Shares Outstanding of 7048962 and a Short% of Float of 14.95.

Most Popular